Gu Laboratory
Shengqing (Stan) Gu
Principal Investigator
- Departments, Labs and Institutes
- Labs
- Gu Laboratory
Areas of Research
- Immunology
- Immunotherapy
- Computational Biology
- CRISPR Screens
- Single-Cell Genomics
- Epigenetics
- Tumor Heterogeneity
Our lab is interested in enhancing the efficacy of cancer therapies, especially immunotherapy, by modulating cell-cell interactions. To achieve this goal, we integrate various cutting-edge experimental and computational approaches in the areas of functional genomics, single-cell/spatial multi-omics, data mining, machine learning and mathematical modeling, among others.
Current research directions
- Context-dependent regulation of cancer antigen presentation
- Novel mechanisms of cell-cell interaction
- Dynamics of the anti-cancer immune response
Recent publications
- Zexian Zeng*, Shengqing Stan Gu*, Carly Tymm, Yufeng He, Lin Yang, Ce Luo, Cheryl J Wong, Dian Li, Nofal Ouardaoui, Wubing Zhang, Xiaoqing Wang, Jason L Weirather, Scott J Rodig, F Stephen Hodi#, Myles Brown#, X Shirley Liu#. Hippo signaling pathway regulates cancer cell-intrinsic MHC-II expression. Cancer Immunology Research. 10(12):1559-1569. (* Co-first author; # Co-corresponding author) PMID: 36219700.
- Xiaoqing Wang*, Collin Tokheim*, Shengqing Stan Gu*, Binbin Wang*, Qin Tang, Yihao Li, Nicole Traugh, Zexian Zeng, Yi Zhang, Ziyi Li, Boning Zhang, Jingxin Fu, Tengfei Xiao, Wei Li, Clifford Meyer, Jun Chu, Peng Jiang, Paloma Cejas, Klothilda Lim, Henry Long, Myles Brown#, X Shirley Liu# (2021). In vivo CRISPR screens identify E3 ligase Cop1 as a cancer immunotherapy target by modulating macrophage infiltration. Cell. 184(21):5357-5374.e22. (* Co-first author; # Co-corresponding author) PMCID: PMC9136996.
- Shengqing Stan Gu*, Wubing Zhang*, Xiaoqing Wang*, Peng Jiang*, Nicole Traugh, Ziyi Li, Clifford Meyer, Blair Stewig, Yingtian Xie, Xia Bu, Michael P Manos, Alba Font-Tello, Evisa Gjini, Ana Lako, Jake Conway, Alok K Tewari, Zexian Zeng, Avinash Das Sahu, Collin Tokheim, Jason L Weirather, Jingxin Fu, Yi Zhang, Benjamin Kroger, Jin-Hua Liang, Paloma Cejas, Gordon J Freeman, Scott Rodig, Henry W Long, Benjamin E Gewurz, F Stephen Hodi, Myles Brown#, X Shirley Liu# (2021). Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discovery. 11(6):1524-1541. (* Co-first author; # Co-corresponding author) PMCID: PMC8543117. (Cover story of the issue)
- Shengqing Gu, Stephanie Lheureux, Azin Sayad, Paulina Cybulska, Liat Hogen, Iryna Vyarvelska, Dongsheng Tu, Wendy Parulekar, Matthew Nankivell, Sean Kehoe, Dennis Chi, Douglas A Levine, Marcus Q Bernardini, Barry Rosen, Amit Oza, Myles Brown#, Benjamin G Neel# (2021). Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc Natl Acad Sci U S A. 118(25): e2026663118. (# Co-corresponding author) PMCID: PMC8237655.
- Shengqing Stan Gu*, Xiaoqing Wang*, Xihao Hu*, Peng Jiang, Ziyi Li, Nicole Traugh, Xia Bu, Qin Tang, Chenfei Wang, Zexian Zeng, Jingxin Fu, Clifford Meyer, Yi Zhang, Paloma Cejas, Klothilda Lim, Jin Wang, Wubing Zhang, Collin Tokheim, Avinash Das Sahu, Xiaofang Xing, Benjamin Kroger, Zhangyi Ouyang, Henry Long, Gordon J Freeman#, Myles Brown#, X Shirley Liu# (2020). Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biology. 21(1):263. (* Co-first author; # Co-corresponding author) PMCID: PMC7559192.
- Sailing Shi*, Shengqing Gu*, Tong Han, Wubing Zhang, Lei Huang, Ziyi Li, Deng Pan, Jingxin Fu, Jun Ge, Myles Brown, Peng Zhang, Peng Jiang#, Kai W Wucherpfennig#, X Shirley Liu# (2020). Inhibition of MAN2A1 enhances the immune response to anti-PD-L1 in human tumors. Clinical Cancer Research. 26(22):5990-6002. (* Co-first author; # Co-corresponding author) PMCID: PMC8500537.
- Peng Jiang*, Shengqing Gu*, Deng Pan*, Jingxin Fu, Ziyi Li, Nicole Traugh, Xia Bu, Bo Li, Jun Liu, Gordon Freeman, Myles Brown, Kai W Wucherpfennig#, X Shirley Liu# (2018). Signatures of T-cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine. 24(10):1550-1558. (* Co-first author; # Co-corresponding author) PMCID: PMC6487502.
- Shengqing Gu, Azin Sayad, Gordon Chan, Wentian Yang, Zhibin Lu, Carl Virtanen, Richard A Van Etten, Benjamin G Neel (2018). SHP2 is required for BCR-ABL1-induced hematologic neoplasms. Leukemia. 32(1):203-213. PMCID: PMC6005183.
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.